Prescription drug · NDA
Vigafyde (Vigabatrin) NDC 80789-003
Vigabatrin 100 mg/mL · Solution · Oral · Upsher-Smith Laboratories, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 80789-003-15 | 8078900031580789000315 | 1 BOTTLE in 1 CARTON (80789-003-15) / 150 mL in 1 BOTTLEMarketed from Aug 26, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Vigafyde
- Generic name (nonproprietary)
- vigabatrin
- Active ingredients
- Vigabatrin — 100 mg/mL
- Dosage form
- Solution
- Route
- Oral
- Labeler
- Upsher-Smith Laboratories, LLCNDC labeler code 80789
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 217684
- Marketing start
- Listing expires
- Identifiers
- Product ID 80789-003_43aeb38a-b4ee-47ed-8239-c488b074f1c9SPL ID 43aeb38a-b4ee-47ed-8239-c488b074f1c9SPL set ID 8d3d6316-33ab-41e8-9485-4495c218be56RxCUI 2685217, 2685223UNII GR120KRT6K
- Pharmacologic class
- Anti-epileptic Agent
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N480789000315followed by a unit qualifier and the quantityPackage 80789-0003-15. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
VIGAFYDE is indicated as monotherapy for the treatment of i nfantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss. ( 1 ) VIGAFYDE is indicated as monotherapy for the treatment of infantile spasms in pediatric patients 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions ( 5.1 )].
Excerpt only. Read the full label for complete information.
About NDC 80789-003
- What is NDC 80789-003?
- 80789-003 is the product NDC for Vigafyde (vigabatrin), Vigabatrin 100 mg/mL solution, listed with the FDA by Upsher-Smith Laboratories, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Vigafyde (Vigabatrin).
- What is the active ingredient?
- Vigabatrin.
- Who is the labeler?
- Upsher-Smith Laboratories, LLC, NDC labeler code 80789. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Vigafyde?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.